// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
PARP inhibitors improve outcomes in BRCA1/2-mutant or HRD-positive ovarian cancer
SOLO-1, PAOLA-1, PRIMA — established maintenance setting.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →A
ctDNA-positive MRD predicts recurrence in stage II/III colorectal cancer
GALAXY/CIRCULATE-Japan, BESPOKE, multiple cohorts; HR ~10–30 for relapse.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →C
Adjuvant chemotherapy intensification based on ctDNA MRD improves overall survival
DFS signal in DYNAMIC; OS benefit not yet established. Active phase III work.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →C
Multi-cancer early detection (MCED) tests like Galleri reduce cancer mortality in average-risk adults
Sensitivity for stage I disease modest (~17%); SYMPLIFY shows utility for symptomatic triage; mortality endpoint requires NHS-Galleri readout.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →B
Tumor mutational burden (TMB) predicts checkpoint-inhibitor response across all solid tumors
Validated in NSCLC, melanoma, MSI-H/dMMR; pan-tumor cutoffs (≥10 mut/Mb) are imperfect.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →